Auckland Uniservices Limited

Xenova Limited

Vetdc, Inc.

Pathway Therapeutics Inc.

Guangzhou Institute of Biomedicine and Health

Mei Pharma, Inc.

Swarnalatha Akuratiya Gamage

Gordon William Rewcastle

William Alexander Denny

Anna Giddens

Jack Urquhart Flanagan

Kit Yee Tsang

Brian Desmond Palmer

Julie Ann Spicer

Lai Ming Ching

Anna Claire Giddens

Jeffrey Bruce Smaill

Ke Ding

Adam Vorn Patterson

Zhengchao Tu

Amir Ashoorzadeh

Nigel Vicker

Christopher Paul Guise

Muriel Bonnet

Guo-Liang Lu

Xiaomei Ren

Christina Maree Buchanan

Stephen Michael Frazer Jamieson

John Milton

Christopher John Squire

Matthew Roy Bull

Shuang Jiang

Michael Wright

David Frank Hayman

Maria Rosaria Abbattista

Logan James Voss

Martyn Gregory Harvey

Jiney Jose

James Wallace Sleigh

Angus Cheverton Grey

Xueqiang Li

Andrew James Marshall

Peter Robin Shepherd

Gordon Wiliam Rewcastle

Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR, N or N-oxide; X is CR, N or N-oxide; Y is CR, N or N-oxide; Z is CR, N or N-oxide; and at least one of W, X, Y, and Z is N or N-oxide; and Rand Rare as defined. Also described are methods of using such compounds in the treatment of various conditions, such as cancer.

Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy

Fibroblast Growth Factor Receptor kinase inhibitors and prodrugs thereof of Formula (I) and their use for the treatment of hyper-proliferative diseases such as retinopathy, psoriasis, rheumatoid arthritis, osteoarthritis, septic arthritis, tumour metastasis, periodontal disease, corral ulceration, proteinuria, coronary thrombosis from atherosclerotic plaque, aneurismal aorta, dystrophobic epidermolysis bullosa, degenerative cartilage loss following traumatic joint injury, osteopenias mediated by MMP activity, tempero mandibular joint disease, and demyelating disease of the nervous system.

FGFR kinase inhibitors and pharmaceutical uses

Disclosed are tricyclic heterocyclic compounds having kinase inhibitory activity, pharmaceutical compositions and kits comprising the compounds, and use of the compounds in the treatment of or in medicaments for the treatment of various diseases and conditions. In particular, disclosed are tricyclic heterocyclic compounds of the formula (I) having CSF-1R (c-FMS kinase) inhibitory activity and their use in the treatment of various diseases and conditions, such as those mediated by CSF-1R, including proliferative or neoplastic diseases and conditions, including cancers, and bone, inflammatory, and autoimmune diseases and conditions.

Tricyclic heterocyclic derivatives and uses thereof

Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR, N or N-oxide; X is CR, N or N-oxide; Y is CR, N or N-oxide; Z is CR, N or N-oxide; and at least one of W, X, Y, and Z is N or N-oxide; and Rand Rare as defined. Also described are methods of using such compounds in the treatment of various conditions, such as cancer. 

The present invention relates to ketamine derivatives of the formula (I), pharmaceutical compositions comprising them, and methods for treating pain comprising administering them, and their use in the manufacture of medicaments for treating pain. The present invention also relates to methods for anaesthetizing and methods for sedating a subject comprising administering ketamine derivatives of the formula (II).

Ketamine derivatives

Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides, e.g., compounds of Formulae IA, IB, and IC, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs. 

Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy

Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazoles of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs. 

Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy

Pharmaceutical compounds

Process for the preparation of

Growing community of inventors

Auckland, New Zealand

Swarnalatha Akuratiya Gamage